Brain & Breakfast

Join a live panel discussion — hosted by SwedenBio and PharmaLex (Cencora)

The new Joint Clinical Assessment (JCA) promises big change in how products go to market. Are you ready for it? An upcoming live panel discussion — hosted by SwedenBio and PharmaLex (Cencora) — will share what you need to know about this new regulation. If you are launching a product into Europe and Sweden, this might interest you.

You don’t want to miss:

  • Why the JCA matters and what you can expect from the framework
  • Key insights about the JCA’s process from the pilot phase
  • How the JCA impact patient access for your products
  • The opportunities and challenges ahead

The 𝗘𝗨 𝗝𝗖𝗔 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 as part of the 𝗘𝗨 𝗛𝗧𝗔 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻, seeking to substitute multiple country-specific clinical assessments and establish a more streamlined and transparent single market for health technologies, will pose both a threat and an opportunity for getting innovative medicines to patients in Europe and Sweden.


8.30 – 9.00 Breakfast and mingle

9.00 – 9.30 Panel discussion

9.30 – 9.45 Ask the experts

10.00 Close

More info TBA